Two recent studies confirm that CRISPR/Cas9 can edit and inhibit latent HIV provirus, but one of them hints that the virus can develop resistance to excision.
Researchers used viral repertoire sequencing to characterize an early-stage HIV-neutralizing antibody, an important step toward developing a vaccine.
The firm's dual assay for host antigen to HIV as well as viral RNA was described in a proof-of-principle study earlier this year.
The company'sExatype software is a web-based solution for locating HIV drug resistance mutations using raw NGS data and other functional information.
The firm has improved design of the system for low-resource settings and validated it on clinical chlamydia samples and extracted HIV, Ebola, and dengue samples.
The companies will work to develop an affordable, portable, and easy-to-use HIV quantitative viral load test using Cue's Lab-In-A-Box MDx platform.
In a pilot study involving 230 HIV-infected patients, the researchers tested the implementation of privacy-preserving genetic testing, using homomorphic encryption.
The Collaborative African Genomics Network recently finished its second year of grant funding, hitting many of its milestones, and is already digging into the work for their third year.
The test, part of a planned menu expansion, runs on the integrated, automated Roche Cobas 6800 and 8800 platforms.
The funding will support research into epigenomic or ncRNA regulatory mechanisms in HIV/AIDS infection in the context of substance abuse and addiction.
Retraction Watch reports that a paper was pulled because it refers to a gene that doesn't exist in mice.
Researchers were able to generate fertilized northern white rhinoceros eggs, according to Mashable.
Former Orig3n employees raise concerns about its testing at Bloomberg Businessweek.
In PLOS this week: microRNA expression changes in hepatocellular carcinoma, real-time PCR-based approach for diagnosing schistosomiasis, and more.